Literature DB >> 11823399

Intranasal fentanyl provides adequate postoperative analgesia in pediatric patients.

Ray Manjushree1, Aparna Lahiri, Bablu Rani Ghosh, Arpita Laha, Krishna Handa.   

Abstract

PURPOSE: To evaluate intranasally administered fentanyl for postoperative analgesia in pediatric patients.
METHODS: Thirty-two children aged four to eight years, ASA physical status I and II were included in this prospective randomized controlled study. In the postoperative care unit, patients were allocated to receive fentanyl, using a double-blind study design, either intranasally (Group I) or intravenously (Group II) in small titrated doses until they became pain free or side effects appeared which prohibited continuation of the drug.
RESULTS: Satisfactory analgesia was achieved in both groups, though the required drug dosage was higher in the intranasal group (1.43 +/- 0.39 microg.kg(-1)). Onset of analgesia tended to be slower via the intranasal route compared to the iv route (13 +/- 4.5 vs 8.3 +/- 3.08 min; P=not significant). Side effects observed in this series were within an acceptable range and similar for both modalities.
CONCLUSION: The intranasal route provides a good alternative for administration of fentanyl in pediatric surgical patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11823399     DOI: 10.1007/bf03020494

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   5.063


  9 in total

1.  Intranasal fentanyl versus placebo for pain in children during catheterization for voiding cystourethrography.

Authors:  Seen Chung; Ruth Lim; Ran D Goldman
Journal:  Pediatr Radiol       Date:  2010-02-24

2.  Intranasal sufentanil/midazolam versus ketamine/midazolam for analgesia/sedation in the pediatric population prior to undergoing multiple dental extractions under general anesthesia: a prospective, double-blind, randomized comparison.

Authors:  J A Roelofse; E A Shipton; C J de la Harpe; R J Blignaut
Journal:  Anesth Prog       Date:  2004

3.  Formulations of fentanyl for the management of pain.

Authors:  Sina Grape; Stephan A Schug; Stefan Lauer; Barbara S Schug
Journal:  Drugs       Date:  2010       Impact factor: 9.546

4.  Intranasal fentanyl versus intravenous morphine in the emergency department treatment of severe painful sickle cell crises in children: study protocol for a randomised controlled trial.

Authors:  Michael Joseph Barrett; John Cronin; Adrian Murphy; Siobhan McCoy; John Hayden; SinéadNic an Fhailí; Tim Grant; Abel Wakai; Corrina McMahon; Sean Walsh; Ronan O'Sullivan
Journal:  Trials       Date:  2012-05-30       Impact factor: 2.279

5.  Evaluation of the effects of botulinum toxin A injections when used to improve ease of care and comfort in children with cerebral palsy whom are non-ambulant: a double blind randomized controlled trial.

Authors:  Megan Thorley; Samantha Donaghey; Priya Edwards; Lisa Copeland; Megan Kentish; Kim McLennan; Jayne Lindsley; Laura Gascoigne-Pees; Leanne Sakzewski; Roslyn N Boyd
Journal:  BMC Pediatr       Date:  2012-08-09       Impact factor: 2.125

6.  Role of intranasal fentanyl in breakthrough pain management in cancer patients.

Authors:  Wojciech Leppert
Journal:  Cancer Manag Res       Date:  2010-09-30       Impact factor: 3.989

Review 7.  Management of breakthrough pain in children with cancer.

Authors:  Stefan J Friedrichsdorf; Andrea Postier
Journal:  J Pain Res       Date:  2014-03-07       Impact factor: 3.133

8.  Pain care for patients with epidermolysis bullosa: best care practice guidelines.

Authors:  Kenneth R Goldschneider; Julie Good; Emily Harrop; Christina Liossi; Anne Lynch-Jordan; Anna E Martinez; Lynne G Maxwell; Danette Stanko-Lopp
Journal:  BMC Med       Date:  2014-10-09       Impact factor: 8.775

9.  Intranasal fentanyl for respiratory distress in children and adolescents with life-limiting conditions.

Authors:  Lucas Pieper; Julia Wager; Boris Zernikow
Journal:  BMC Palliat Care       Date:  2018-09-10       Impact factor: 3.234

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.